The first vaccine against the world's fastest growing mosquito-borne disease, dengue virus, has been granted marketing authorisation in Mexico. Sanofi Pasteur's Dengvaxia has been approved for prevention against four dengue virus serotypes in adults, adolescents and pre-adolescents, aged 9-45 years, by the COFEPRIS (The Federal Commission for the Protection against Sanitary Risks).
The price of the vaccine has not yet been established; Sanofi said its next steps would involve discussions with the...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
